BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
BEIGENEBEIGENE(US:ONC) Businesswire·2025-10-20 10:00

Core Insights - BeOne Medicines Ltd. presented data from two pivotal Phase 3 trials, RATIONALE-307 and 312, at the ESMO 2025 Congress, highlighting the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab) [1] Group 1: Clinical Trials - The results from the RATIONALE-307 and 312 trials provide new evidence supporting the efficacy of TEVIMBRA in treating lung cancer [1] - The data reinforces TEVIMBRA's consistent and durable efficacy across various lung cancer types [1]